CNS Drugs
November 28, 2025
D J Hirsch, Jace Reed, Aasim Naqvi et al.
2 citations
Eating disorders (EDs) are complex psychiatric conditions characterized by disruptions in eating behaviors, body image concerns, and profound medical and psychosocial consequences. Despite their significant global prevalence, coupled with high morbidity and mortality rates, pharmacological treatment options remain limited. This review synthesizes evidence from clinical drug trials conducted...
OBM Integrative and Complementary Medicine
June 25, 2018
Jonathan Dang, Luma Bashmi, Stephen Meeneghan et al.
2 citations
Background: An increasing number of patients and practitioners are using mindfulness meditation programs despite uncertainty about the evidence supporting these programs’ health benefits. Aim: To review the current evidence on the effectiveness of mindfulness-based interventions (MBI) on depressive symptoms and quality of life (QOL) among patients with depression comorbid medical conditions and...
Translational Psychiatry
June 15, 2018
Brigitte Vanle, William Olcott, Jaime Jimenez et al.
Among patients with Parkinson's disease (PD), depression is prevalent and disabling, impacting both health outcomes and quality of life. There is a critical need for alternative pharmacological methods to treat PD depression, as mainstream antidepressant drugs are largely ineffective in this population. Currently, there are no recommendations for the optimal treatment of PD neuropsychiatric...
American Psychiatric Publishing eBooks
May 5, 2014
Robert N. Pechnick, Kathryn A. Cunningham, Itai Danovitch
The hallucinogens are a class of psychoactive drugs, either synthetic or plant products, that produce auditory and/or visual hallucinations as well as thought, mood, and perceptual changes. Depending on dosage, expectation (set), and environment (setting), they also can induce euphoria and a state similar to a transcendental experience. These hallucinations can be present as part of a delirium...